gip and glp 1 receptor agonist New strategies for the treatment of obesity metabolic dysfunctions GLP-1 Receptor Agonists Explained for

Accessed July 23, 2023

Jos Manuel Carrascosa has participated as PI/SI and/or guest presenter and/or advisor for Almirall, Janssen, Abbvie, UCB, Boehringer-Ingelheim, Lilly, Novartis, Amgen, BMS, and Sandoz

This suggests that for maximum results, treatment durations of at least 12 to 18 months produce the best outcomes

doi: 10.1136/bmj.i610

10 or 15 mg once weekly) vs Reduce to tirzepatide 5 mg once weekly vs Placebo for 52 weeks (randomized 3:3:2 at week 60) Primary outcome: Percent change in bodyweight from baseline to week 112 Results: Primary outcome (percent change in bodyweight at week 112): Tirzepatide MTD -21.9%, Tirzepatide 5 mg -16.6%, Placebo -9.9% (estimated treatment difference vs placebo -12.0% for MTD and -6.6% for 5 mg